Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?: Grand...

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Evidence Review

Background:

• Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability, affecting approximately 12 million US adults annually.
• Key risk factors include tobacco smoke exposure and other environmental factors.
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 Report provides an evidence-based review for COPD assessment, diagnosis, and treatment.

Observation:

• Current evidence does not conclusively demonstrate that existing COPD medications alter mortality.
• Inhaled bronchodilators are the primary treatment for COPD.
• The role and risks of inhaled corticosteroids (ICS), including increased pneumonia risk, are debated in COPD management.

Findings:

• The review highlights the need for careful consideration of inhaled corticosteroid indications in severe COPD.
• Expert discussion focuses on when to initiate and withdraw inhaled corticosteroids.
• Alternative and adjunctive treatments for COPD exacerbations and recurrent pneumonia are explored.

Implications:

• This expert reflection emphasizes individualized treatment strategies for COPD, balancing benefits and risks of inhaled corticosteroids.
• It underscores the importance of reassessing inhaled corticosteroid use in patients with frequent exacerbations and pneumonia.
• The discussion guides clinicians in optimizing COPD care beyond standard bronchodilator therapy.